Florence, MA, United States of America

Michelle Chan

This inventor holds 4 USPTO granted patents and 2 EPO patents. Top assignee: Glaxosmithkline Biologicals Sa. Active years: 2017-2021.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.7

ph-index = 4

Forward Citations = 49(Granted Patents)


Company Filing History:


Years Active: 2017-2021

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Michelle Chan

Introduction

Michelle Chan is a prominent inventor based in Florence, MA (US), known for her significant contributions to the field of biotechnology. With a total of four patents to her name, she has made remarkable strides in developing innovative solutions that enhance the delivery of therapeutic agents.

Latest Patents

Among her latest inventions are cationic oil-in-water emulsions. These emulsions contain high concentrations of cationic lipids and are characterized by a defined oil-to-lipid ratio. The cationic lipids interact with negatively charged molecules, effectively anchoring them to the emulsion particles. This technology is particularly useful for delivering negatively charged molecules, such as nucleic acid molecules, to cells and for formulating nucleic acid-based vaccines.

Career Highlights

Michelle Chan has established herself as a key figure in her field through her innovative work at GlaxoSmithKline Biologicals SA. Her research focuses on enhancing the efficacy of drug delivery systems, which has the potential to revolutionize treatments in various medical applications.

Collaborations

Throughout her career, Michelle has collaborated with notable colleagues, including Luis Brito and Andrew John Geall. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and the advancement of scientific knowledge.

Conclusion

Michelle Chan's contributions to biotechnology, particularly in the development of cationic oil-in

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…